Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

Rhea-AI Summary

Organogenesis Holdings (NASDAQ: ORGO) reported strong Q4 2024 financial results with net revenue of $126.7 million, up 27% from Q4 2023. The company achieved Q4 net income of $7.7 million compared to a net loss of $0.6 million in Q4 2023.

For full-year 2024, revenue reached $482.0 million, an 11% increase from 2023, driven by Advanced Wound Care products (+12% to $453.6M) and Surgical & Sports Medicine products (+3% to $28.4M). The company ended 2024 with $136.2 million in cash and no outstanding debt.

For 2025 guidance, Organogenesis expects:

• Net revenue between $480.0-$535.0 million
• Net income between $9.5-$38.8 million
• Adjusted EBITDA between $43.6-$83.2 million

The company also plans to submit the ReNu BLA by end of 2025, targeting knee OA treatment.

Positive

• Q4 revenue up 27% YoY to $126.7M
• Q4 net income improved to $7.7M from -$0.6M loss
• Full year revenue up 11% to $482M
• Improved cash position to $136.2M with zero debt
• Gross margin increased to 75% in Q4 2024

Negative

• Full year net income decreased to $0.9M from $4.9M
• Operating loss of $1.3M vs operating income of $12.5M in 2023
• $18.8M impairment and $4.0M write-down expenses in 2024
• Operating expenses increased 17% to $367.6M

CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2024.

Fourth Quarter 2024 Financial Results Summary:

• Net revenue of $126.7 million for the fourth quarter of 2024, an increase of $27.0 million compared to net revenue of $99.7 million for the fourth quarter of 2023. Net revenue for the fourth quarter of 2024 consists of:
  • Net revenue from Advanced Wound Care products of $118.6 million, an increase of 27% from the fourth quarter of 2023.
  • Net revenue from Surgical & Sports Medicine products of $8.1 million, an increase of 24% from the fourth quarter of 2023.
• Net income of $7.7 million for the fourth quarter of 2024, compared to net loss of $0.6 million for the fourth quarter of 2023, an increase in net income of $8.3 million.
• Adjusted EBITDA of $18.2 million for the fourth quarter of 2024, compared to Adjusted EBITDA of $7.5 million for the fourth quarter of 2023, an increase of $10.7 million.
• Adjusted net income of $8.8 million for the fourth quarter of 2024, compared to adjusted net income of $1.9 million for the fourth quarter of 2023, an increase of $6.8 million.

Fiscal Year 2024 Financial Results Summary:

• Net revenue of $482.0 million for the year ended December 31, 2024, an increase of $48.9 million compared to net revenue of $433.1 million for the year ended December 31, 2023. Net revenue for the year ended December 31, 2024 consists of:
  • Net revenue from Advanced Wound Care products of $453.6 million, an increase of 12% year over year.
  • Net revenue from Surgical & Sports Medicine products of $28.4 million, an increase of 3% year over year.
• Net income of $0.9 million for the year ended December 31, 2024, compared to net income of $4.9 million for the year ended December 31, 2023, a decrease of $4.0 million.
• Adjusted EBITDA of $49.8 million for the year ended December 31, 2024, compared to Adjusted EBITDA of $42.6 million for the year ended December 31, 2023, an increase of $7.2 million.
• Adjusted net income of $20.5 million for the year ended December 31, 2024, compared to adjusted net income of $12.7 million for the year ended December 31, 2023, an increase of $7.8 million.

“Our 2024 results exceeded expectations in a difficult environment, underscoring our strong execution, brand equity and the trust of our customers to help them navigate this complex market,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. “In 2025, we will continue to focus on our customers while we collaborate with policy and law makers to craft a solution that addresses spending while ensuring access to safe and effective therapies for all patients.”

Mr. Gillheeney, Sr. continued: “We expect to meet a key strategic milestone in 2025 by delivering the ReNu BLA submission by the end of the year. We believe this is a transformational opportunity for Organogenesis in that, if approved, ReNu will potentially address an unmet clinical need for all patients suffering from knee OA. ”

Fourth Quarter 2024 Financial Results:

	Three Months Ended December 31,								Change
	2024				2023				$				%
	(in thousands, except for percentages)
Advanced Wound Care	$	118,585			$	93,165			$	25,420				27	%
Surgical & Sports Medicine		8,071				6,486				1,585				24	%
Net revenue	$	126,656			$	99,651			$	27,005				27	%

Net revenue for the fourth quarter of 2024 was $126.7 million, compared to $99.7 million for the fourth quarter of 2023, an increase of $27.0 million, or 27%. The increase in net revenue was driven by an increase of $25.4 million, or 27%, in net revenue for Advanced Wound Care products, and an increase of $1.6 million, or 24%, in net revenue for Surgical & Sports Medicine products.

Gross profit for the fourth quarter of 2024 was $95.6 million, or 75% of net revenue, compared to $71.9 million, or 72% of net revenue for the fourth quarter of 2023, an increase of $23.7 million, or 33%.

Operating expenses for the fourth quarter of 2024 were $85.4 million compared to $73.2 million for the fourth quarter of 2023, an increase of $12.2 million, or 17%. R&D expense was $11.5 million for the fourth quarter of 2024, compared to $11.8 million for the fourth quarter of 2023, a decrease of $0.3 million, or 3%. Selling, general and administrative expenses were $73.9 million for the fourth quarter of 2024, compared to $61.4 million for the fourth quarter of 2023, an increase of $12.5 million, or 20%.

Operating income for the fourth quarter of 2024 was $10.2 million, compared to an operating loss of $1.3 million for the fourth quarter of 2023, an increase in operating income of $11.5 million, or 905%.

Total other expense, net, for the fourth quarter of 2024 was less than $0.1 million, compared to $0.5 million for the fourth quarter of 2023, a decrease of $0.5 million, or 95%.

Net income for the fourth quarter of 2024 was $7.7 million, or $0.05 per share, compared to a net loss of $0.6 million, or $0.00 per share, for the fourth quarter of 2023, an increase in net income of $8.3 million, or $0.05 per share.

Adjusted EBITDA was $18.2 million for the fourth quarter of 2024, compared to $7.5 million for the fourth quarter of 2023, an increase of $10.7 million, or 143%.

Adjusted net income was $8.8 million for the fourth quarter of 2024, compared to $1.9 million for the fourth quarter of 2023, an increase of $6.8 million, or 354%.

As of December 31, 2024, the Company had $136.2 million in cash, cash equivalents and restricted cash and no outstanding debt obligations, compared to $104.3 million in cash, cash equivalents and restricted cash and $66.2 million in net debt obligations as of December 31, 2023.

Fiscal Year 2024 Financial Results:

	Year Ended December 31,								Change
	2024				2023				$				%
	(in thousands, except for percentages)
Advanced Wound Care	$	453,639			$	405,514			$	48,125				12	%
Surgical & Sports Medicine		28,404				27,626				778				3	%
Net revenue	$	482,043			$	433,140			$	48,903				11	%

Net revenue for the year ended December 31, 2024 was $482.0 million, compared to $433.1 million for the year ended December 31, 2023, an increase of $48.9 million, or 11%. The increase in net revenue was driven by an increase of $48.1 million, or 12%, in net revenue for Advanced Wound Care products and an increase of $0.8 million, or 3%, in net revenue for Surgical & Sports Medicine products.

Gross profit for the year ended December 31, 2024 was $366.3 million, or 76% of net revenue, compared to $326.7 million, or 75% of net revenue for the year ended December 31, 2023, an increase of $39.6 million, or 12%.

Operating expenses for the year ended December 31, 2024 were $367.6 million compared to $314.1 million for the year ended December 31, 2023, an increase of $53.5 million or 17%. R&D expense was $50.3 million for the year ended December 31, 2024, compared to $44.4 million for the year ended December 31, 2023, an increase of $5.9 million, or 13%. Selling, general and administrative expenses were $294.5 million for the year ended December 31, 2024, compared to $269.8 million for the year ended December 31, 2023, an increase of $24.8 million, or 9%. For the year ended December 31, 2024, the Company recorded impairment and write down expenses of $18.8 million and $4.0 million, respectively.

Operating loss for the year ended December 31, 2024 was $1.3 million, compared to operating income of $12.5 million for the year ended December 31, 2023, a decrease in operating income of $13.8 million, or 110%.

Total other expense, net, for the year ended December 31, 2024, was $1.5 million, compared to $2.1 million for the year ended December 31, 2023, a decrease of $0.6 million, or 29%.

Net income for the year ended December 31, 2024 was $0.9 million, or $(0.01) per share, compared to net income of $4.9 million or $0.04 per share, for the year ended December 31, 2023, a decrease in net income of $4.0 million, or $(0.05) per share.

Adjusted EBITDA was $49.8 million for the year ended December 31, 2024, compared to $42.6 million for the year ended December 31, 2023, an increase of $7.2 million, or 17%.

Adjusted net income was $20.5 million for the year ended December 31, 2024, compared to $12.7 million for the year ended December 31, 2023, an increase in adjusted net income of $7.8 million, or 61%.

As of December 31, 2024, the Company had $136.2 million in cash, cash equivalents and restricted cash and no outstanding debt obligations, compared to $104.3 million in cash, cash equivalents and restricted cash and $66.2 million in net debt obligations as of December 31, 2023.

Fiscal Year 2025 Guidance:

For the year ending December 31, 2025, the Company expects:

• Net revenue between $480.0 million and $535.0 million, representing a range of roughly flat to an increase of approximately 11% year-over-year, as compared to net revenue of $482.0 million for the year ended December 31, 2024.
  • The 2025 net revenue guidance range assumes:
    • Net revenue from Advanced Wound Care products between $450.0 million and $500.0 million, a decrease of 1% to an increase of 10% year-over-year as compared to net revenue of $453.6 million for the year ended December 31, 2024.
    • Net revenue from Surgical & Sports Medicine products between $30.0 million and $35.0 million, an increase of 6% to 23% year-over-year as compared to net revenue of $28.4 million for the year ended December 31, 2024.
• Net income between $9.5 million and $38.8 million and adjusted net income between $15.3 million and $44.6 million.
• EBITDA between $27.0 million and $66.6 million and Adjusted EBITDA between $43.6 million and $83.2 million.

Fourth Quarter Earnings Conference Call:

Management will host a conference call at 5:00 p.m. Eastern Time today to discuss the results of the quarter and fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED BALANCE SHEETS (amounts in thousands, except share and per share data)
	December 31,
	2024				2023
Assets
Current assets:
Cash and cash equivalents	$	135,571			$	103,840
Restricted cash		580				498
Accounts receivable, net of allowance for credit losses of $9,576 and $6,860		109,861				81,999
Inventories, net		26,219				28,253
Prepaid expenses and other current assets		13,710				10,454
Total current assets		285,941				225,044
Property and equipment, net		89,128				116,228
Intangible assets, net		12,468				15,871
Goodwill		28,772				28,772
Operating lease right-of-use assets, net		37,110				40,118
Deferred tax asset, net		39,462				28,002
Other assets		5,005				5,990
Total assets	$	497,886			$	460,025
Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity
Current liabilities:
Current portion of term loan	$	—			$	5,486
Current portion of finance lease obligations		1,170				1,081
Current portion of operating lease obligations - related party		3,671				8,413
Current portion of operating lease obligations		4,272				4,731
Accounts payable		28,911				30,724
Accrued expenses and other current liabilities		39,453				30,074
Total current liabilities		77,477				80,509
Term loan, net of current portion		—				60,745
Finance lease obligations, net of current portion		718				1,888
Operating lease obligations, net of current portion - related party		8,283				11,954
Operating lease obligations, net of current portion		25,198				25,053
Other liabilities		894				1,213
Total liabilities		112,570				181,362
Commitments and contingencies (Note 20)
Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 and 0 shares authorized, issued and outstanding at December 31, 2024 and 2023, respectively; liquidation preference of $131,387 and $0 at December 31, 2024 and 2023, respectively.		122,419				—
Stockholders’ equity:
Preferred stock, $0.0001 par value; 870,000 and 1,000,000 shares authorized at December 31, 2024 and 2023, respectively; none issued or outstanding		—				—
Common stock, $0.0001 par value; 400,000,000 shares authorized; 126,458,784 and 132,044,944 shares issued; 125,730,236 and 131,316,396 shares outstanding at December 31, 2024 and 2023, respectively		13				13
Additional paid-in capital		302,994				319,621
Accumulated deficit		(40,110	)			(40,971	)
Total stockholders' equity		262,897				278,663
Total liabilities, redeemable convertible preferred stock, and stockholders' equity	$	497,886			$	460,025

ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)  (amounts in thousands, except share and per share data)
	Three Months Ended December 31,								Year Ended December 31,
	2024				2023				2024				2023
Net revenue	$	126,656			$	99,651			$	482,043			$	433,140
Cost of goods sold		31,051				27,769				115,741				106,481
Gross profit		95,605				71,882				366,302				326,659
Operating expenses:
Selling, general and administrative		73,856				61,381				294,513				269,754
Research and development		11,530				11,770				50,271				44,380
Impairment of property and construction		—				—				18,842				—
Write down of capitalized internal-use software costs		—				—				3,959				—
Total operating expenses		85,386				73,151				367,585				314,134
Income (loss) from operations		10,219				(1,269	)			(1,283	)			12,525
Other expense, net:
Interest expense, net		61				(502	)			(1,544	)			(2,190	)
Other income (expense), net		(27	)			(25	)			20				57
Total other income (expense), net		34				(527	)			(1,524	)			(2,133	)
Net income (loss) before income taxes		10,253				(1,796	)			(2,807	)			10,392
Income tax (expense) benefit		(2,580	)			1,228				3,668				(5,447	)
Net income (loss) and comprehensive income (loss)	$	7,673			$	(568	)		$	861			$	4,945
Accretion of redeemable convertible preferred stock to redemption value		(412	)			—				(412	)			—
Cumulative dividend on redeemable convertible preferred stock		(1,386	)			—				(1,386	)			—
Net income (loss) attributable to common stockholders		5,875				(568	)			(937	)			4,945
Net income (loss), per share:
Basic	$	0.05			$	0.00			$	(0.01	)		$	0.04
Diluted	$	0.04			$	0.00			$	(0.01	)		$	0.04
Weighted-average common shares outstanding
Basic		129,679,843				130,916,950				131,673,278				131,231,317
Diluted		132,162,370				131,857,509				131,673,278				132,746,727

ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS (amounts in thousands, except share and per share data)
	Year Ended December 31,
	2024				2023				2022
Cash flows from operating activities:
Net income	$	861			$	4,945			$	15,532
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		13,623				10,448				5,845
Amortization of intangible assets		3,403				4,918				4,883
Reduction in the carrying value of right-of-use assets		8,348				8,083				7,303
Non-cash interest expense		394				427				434
Deferred interest expense		305				490				501
Deferred tax expense (benefit)		(10,719	)			2,012				1,980
Loss on disposal of property and equipment		1,140				235				4,482
Loss on lease termination		—				559				—
Loss on extinguishment of term loan		215				—				—
Provision recorded for credit losses		3,938				1,297				1,781
Adjustment for excess and obsolete inventories		8,210				6,580				9,648
Stock-based compensation		10,578				8,996				6,552
Impairment of property and construction (Note 8)		18,842				—				—
Write down of capitalized internal-use software costs (Note 8)		3,959				—				—
Changes in operating assets and liabilities:
Accounts receivable		(31,800	)			5,539				(8,770	)
Inventories		(6,204	)			(8,179	)			(9,410	)
Prepaid expenses and other current and other assets		(2,549	)			(10,115	)			(378	)
Operating leases		(14,066	)			(8,439	)			(7,006	)
Accounts payable		(2,372	)			(108	)			3,260
Accrued expenses and other current liabilities		9,164				3,138				(11,850	)
Other liabilities		(1,062	)			91				72
Net cash provided by operating activities		14,208				30,917				24,859
Cash flows from investing activities:
Purchases of property and equipment		(10,032	)			(24,364	)			(33,898	)
Net cash used in investing activities		(10,032	)			(24,364	)			(33,898	)
Cash flows from financing activities:
Term loan repayments under the 2021 Credit Agreement		(66,563	)			(4,688	)			(2,813	)
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs		120,688				—				—
Payments for the repurchase of common stock		(25,479	)			—				—
Principal repayments of finance lease obligations		(1,081	)			(485	)			(200	)
Proceeds from the exercise of stock options		1,247				—				2,070
Payments of withholding taxes in connection with RSUs vesting		(1,175	)			(332	)			(648	)
Payments of deferred acquisition consideration		—				—				(608	)
Net cash provided by (used in) financing activities		27,637				(5,505	)			(2,199	)
Change in cash, cash equivalents and restricted cash		31,813				1,048				(11,238	)
Cash, cash equivalents, and restricted cash, beginning of year		104,338				103,290				114,528
Cash, cash equivalents, and restricted cash, end of year	$	136,151			$	104,338			$	103,290
Supplemental disclosure of cash flow information:
Cash paid for interest	$	4,970			$	5,436			$	2,649
Cash paid for income taxes	$	6,965			$	3,052			$	1,201
Supplemental disclosure of non-cash investing and financing activities:
Cumulative effect adjustment for adoption of ASU No. 2016-13	$	—			$	615			$	—
Deferred acquisition consideration and earnout liability recorded for business acquisition	$	—			$	—			$	828
Change in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	$	(432	)		$	841			$	1,928
Right-of-use assets obtained through operating lease obligations	$	5,109			$	5,869			$	1,350
Right-of-use assets obtained through finance lease obligations	$	—			$	3,454			$	—
Redeemable convertible preferred stock issuance costs included in accrued expenses	$	67			$	—			$	—
Prepaid rent reclassified to right-of-use assets	$	230			$	—			$	—
Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock	$	1,798			$	—			$	—

Non-GAAP Financial Measures

Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA and Adjusted net income to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA and Adjusted net income help identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA and Adjusted net income provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.

Adjusted EBITDA

Adjusted EBITDA consists of GAAP net income excluding: (i) interest expense, net, (ii) income tax expense, (iii) depreciation and amortization, (iv) amortization of intangible assets, (v) stock-based compensation expense, and (vi) additional infrequently occurring adjustments described in more detail below.

The following table presents a reconciliation of GAAP net income to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented:

	Three Months Ended December 31,								Year Ended December 31,
($, in thousands)	2024				2023				2024				2023
Net income (loss)	$	7,673			$	(568	)		$	861			$	4,945
Interest expense, net		(61	)			502				1,544				2,190
Income tax expense		2,580				(1,228	)			(3,668	)			5,447
Depreciation and amortization		3,615				2,982				13,623				10,448
Amortization of intangible assets		834				1,229				3,403				4,918
EBITDA		14,641				2,917				15,763				27,948
Stock-based compensation expense		2,891				2,366				10,578				8,996
Restructuring charge (1)		—				1,918				—				3,796
Legal fees (2)		—				—				—				1,182
Sales retention (3)		—				272				—				694
Impairment of property and construction (4)		—				—				18,842				—
Write down of capitalized internal-use software costs (5)		—				—				3,959				—
Disposal of construction in progress (6)		645				—				645				—
Adjusted EBITDA	$	18,177			$	7,473			$	49,787			$	42,616

(1)  Amounts reflect employee retention and benefits as well as other exit costs associated with our restructuring activities.

(2)  Amount reflects the legal and consulting fees incurred related to the published and subsequently withdrawn 2023 local coverage determinations, or LCDs.

(3)  Amount reflects the compensation expenses related to retention for those sales employees impacted by the published and subsequently withdrawn 2023 LCDs.

(4)  Amount reflects the impairment of a purchased building and associated unfinished construction work.

(5)  Amount reflects the write-down of costs previously capitalized as construction in progress in the development of internal-use software, that we determined have no future value.

(6)  Amount reflects construction in progress terminated and disposed of at one of our Canton, Massachusetts facilities, resulting from our decision to move certain operations to the Smithfield Facility.

Adjusted net income

Adjusted net income is defined as GAAP net income (loss) plus (i) amortization of intangible assets and (ii) additional infrequently occurring adjustments described in more detail below, less the estimated tax on these adjustments.

The following table presents a reconciliation of GAAP net income (loss) to non-GAAP Adjusted net income, for the periods presented:

	Three Months Ended December 31,								Year Ended December 31,
($, in thousands)	2024				2023				2024				2023
Net income (loss)	$	7,673			$	(568	)		$	861			$	4,945
Amortization of intangible assets		834				1,229				3,403				4,918
Restructuring charge (1)		—				1,918				—				3,796
Legal fees (2)		—				—				—				1,182
Sales retention (3)		—				272				—				694
Impairment of property and construction (4)		—				—				18,842				—
Write down of capitalized internal-use software costs (5)		—				—				3,959				—
Disposal of construction in progress (6)		645				—				645				—
Tax on above		(399	)			(923	)			(7,249	)			(2,859	)
Adjusted net income	$	8,753			$	1,928			$	20,461			$	12,676

(1)  Amounts reflect employee retention and benefits as well as other exit costs associated with our restructuring activities.

(2)  Amount reflects the legal and consulting fees incurred related to the published and subsequently withdrawn 2023 LCDs.

(3)  Amount reflects the compensation expenses related to retention for those sales employees impacted by the published and subsequently withdrawn 2023 LCDs.

(4)  Amount reflects the impairment of a purchased building and associated unfinished construction work.

(5)  Amount reflects the write-down of costs previously capitalized as construction in progress in the development of internal-use software, that we determined have no future value.

(6)  Amount reflects construction in progress terminated and disposed of at one of our Canton, Massachusetts facilities, resulting from our decision to move certain operations to the Smithfield Facility.

Projected EBITDA and Adjusted EBITDA

The following table presents a reconciliation of projected GAAP net income (loss) to projected non-GAAP EBITDA and projected non-GAAP Adjusted EBITDA included in our guidance for the year ending December 31, 2025:

	Year Ended December 31,
($, in thousands)	2025L				2025H
Net income	$	9,500			$	38,800
Interest income		(4,000	)			(4,000	)
Income tax expense		3,400				13,600
Depreciation and amortization		14,800				14,800
Amortization of intangible assets		3,300				3,300
EBITDA		27,000				66,600
Stock-based compensation expense		12,000				12,000
BLA submission fee to the FDA		4,600				4,600
Adjusted EBITDA		43,600				83,200

Note: Numbers may not foot or recalculate due to rounding.

Projected Adjusted Net Income (Loss)

The following table presents a reconciliation of projected GAAP net loss to projected non-GAAP adjusted net income included in our guidance for the year ending December 31, 2025:

	Year Ended December 31,
($, in thousands)	2025L				2025H
Net income	$	9,500			$	38,800
Amortization of intangible assets		3,300				3,300
BLA submission fee to the FDA		4,600				4,600
Tax on above		(2,100	)			(2,100	)
Adjusted net (loss) income	$	15,300			$	44,600

Note: Numbers may not foot or recalculate due to rounding.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected revenue, net income (loss), Adjusted net income, EBITDA, and Adjusted EBITDA for fiscal 2024 and the breakdown of expected revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the coverage and reimbursement levels for the Company’s products (including as a result of the recently proposed LCDs scheduled to take effect in April 2025); (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred losses in the current period and prior periods and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production or obtain supply of its products in sufficient quantities to meet demand; (10) the impact of the suspension of commercialization of: (a) ReNu and NuCel in connection with the expiration of the FDA’s enforcement grace period for HCT/Ps on May 31, 2021 and (b) Dermagraft in the second quarter of 2022 pending transition of manufacturing to a new manufacturing facility or a third-party manufacturer; (11) whether the Company is able to obtain regulatory approval for and successfully commercialize ReNu; and (12) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2024 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

FAQ

What was Organogenesis (ORGO) Q4 2024 revenue growth compared to Q4 2023?

ORGO's Q4 2024 revenue grew 27% to $126.7 million, compared to $99.7 million in Q4 2023.

How much did Organogenesis (ORGO) Advanced Wound Care revenue grow in 2024?

Advanced Wound Care revenue grew 12% year-over-year to $453.6 million in 2024.

What is Organogenesis (ORGO) revenue guidance for 2025?

ORGO expects 2025 revenue between $480.0-$535.0 million, representing flat to 11% growth.

What is the status of Organogenesis (ORGO) ReNu BLA submission?

ORGO plans to submit the ReNu BLA by the end of 2025 for knee OA treatment.

How much cash does Organogenesis (ORGO) have as of December 2024?

ORGO had $136.2 million in cash with no outstanding debt as of December 31, 2024.